Physician profile
Susan Bard
NPI 1134387657
$424,716.69
in general payments reported to CMS, 2019-2025
44 companies · $138K in 2025
The $138K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,436 · 2020: $1,163 · 2021: $1,953 · 2022: $26K · 2023: $99K · 2024: $155K · 2025: $138K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $283K · Travel and Lodging: $54K · Food and Beverage: $32K · Consulting Fee: $23K · Education: $89.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $283,150.00 |
| Travel and Lodging | $54,155.28 |
| Food and Beverage | $31,672.68 |
| Consulting Fee | $22,610.00 |
| Education | $89.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310,883.70 | 2019-2025 | Rinvoq, Skyrizi |
| Galderma Laboratories, L.P. | $68,713.45 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| E.R. Squibb & Sons, L.L.C. | $16,176.88 | 2021-2025 | Sotyktu, Zeposia |
| Pfizer INC. | $4,869.46 | 2019-2025 | |
| Lilly USA, LLC | $4,404.53 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $2,137.45 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $2,115.88 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $1,748.95 | 2020-2025 | Otezla, Krystexxa, Otezla |
| Arcutis Biotherapeutics, INC. | $1,639.10 | 2023-2025 | Zoryve |
| Genzyme Corporation | $1,545.36 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,340.08 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $1,267.53 | 2022-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $1,227.41 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $1,134.27 | 2023-2025 | Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $990.86 | 2023-2024 | Vtama |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Bard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.